other material
confidence medium
sentiment neutral
materiality 0.50
Pliant Therapeutics launches underwritten public offering; terminates ATM prospectus
PLIANT THERAPEUTICS, INC.
- Company commenced an underwritten public offering of common stock; terms not disclosed.
- No shares were sold under prior $150M ATM facility from July 2021 to January 2023.
- Existing Sales Agreement with Cantor Fitzgerald remains in effect but no sales until new prospectus filed.
- Offering made via effective shelf registration statement (Form S-3).